Loading
Life sciences · Journal article
Biochem · July 30, 2026
Raises a question worth testing. It does not answer one.
This is a comprehensive narrative review and bibliometric analysis of fisetin, a naturally occurring flavonol, summarizing preclinical and experimental evidence for multiple biological activities and mechanisms of action. The authors identify poor bioavailability, low oral solubility, and absence of rigorous clinical evidence as major barriers to clinical translation, and recommend advanced formulations and clinical trials to advance therapeutic development.
Narrative literature review with bibliometric analysis. Published literature on fisetin and its pharmacological activities, molecular mechanisms, and therapeutic applications; no restriction to human studies described.. Intervention: Fisetin (3,3′,4′,7-tetrahydroxyflavone), a naturally occurring flavonol, and its biological and pharmacological activities. n = 658.
Fisetin exhibited diverse biological activities through modulation of oxidative stress, inflammation, apoptosis, autophagy, mitochondrial function, and cellular senescence Experimental evidence supports therapeutic potential against cancer, cardiovascular, neurodegenerative, metabolic, and infectious diseases Major translational barriers include poor aqueous solubility, low oral bioavailability, rapid metabolism, and limited clinical evidence
Pharmacokinetic profile and bioavailability limitations are identified but no comparative data on delivery system improvements are provided.
Clinicians should regard fisetin as an experimental compound with preclinical promise but insufficient clinical evidence to support therapeutic use. Current barriers to translation include poor bioavailability and lack of rigorous human trials; further development of formulation and clinical validation are required before recommendation in practice.
This is a narrative review and bibliometric analysis synthesizing preclinical and experimental evidence without new clinical data, reporting mechanistic findings and research trends rather than testing a defined clinical hypothesis.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should regard fisetin as an experimental compound with preclinical promise but insufficient clinical evidence to support therapeutic use. Current barriers to translation include poor bioavailability and lack of rigorous human trials; further development of formulation and clinical validation are required before recommendation in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a naturally occurring flavonol present in strawberries, apples, grapes, onions, cucumbers, and other plant sources. It has attracted considerable interest because of its antioxidant, anti-inflammatory, antimicrobial, anticancer, neuroprotective, cardioprotective, and senolytic properties. This review comprehensively evaluated the pharmacological activities, mechanisms of action, translational challenges, and global research trends associated with fisetin. Methods: A comprehensive literature review was conducted to synthesise evidence on the traditional uses, pharmacological properties, molecular mechanisms, and therapeutic applications of fisetin. Bibliometric analysis of publications from 2005 to 2024 was performed using the Web of Science Core Collection. A total of 664 records were retrieved using the keywords “fisetin” and “3,3′,4′,7-tetrahydroxyflavone”. Following refinement using Bibliometrix (version 5.0) and the Biblioshiny interface in RStudio, 658 publications were included in the final analysis. Results: Fisetin exhibited diverse biological activities through modulation of oxidative stress, inflammation, apoptosis, autophagy, mitochondrial function, and cellular senescence. Experimental evidence supports its therapeutic potential against cancer, cardiovascular, neurodegenerative, metabolic, and infectious diseases. However, poor aqueous solubility, low oral bioavailability, rapid metabolism, and limited clinical evidence continue to impede its clinical translation. Nanotechnology-based delivery systems, computational modelling, and multi-omics approaches show promise for improving its pharmacokinetic profile and therapeutic efficacy. Bibliometric findings revealed substantial growth in fisetin research, with China leading scientific output and Africa contributing comparatively few publications. Conclusions: Fisetin is a promising multifunctional phytochemical with broad therapeutic potential. Future research should emphasise advanced formulations, rigorous clinical trials, and international collaboration to accelerate its translation into evidence-based clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.